# PROactive Evaluation of Function to Avoid CardioToxicity

> **NCT03862131** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 49 (actual)

## Conditions studied

- Cardiotoxicity
- Breast Cancer
- Lymphoma
- Sarcoma
- Leukemia
- Myeloma
- Lung Cancer

## Interventions

- **DEVICE:** MyoStrain®

## Key facts

- **NCT ID:** NCT03862131
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-13
- **Primary completion:** 2024-06-14
- **Final completion:** 2024-06-14
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Insufficient funding/staff
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862131, "PROactive Evaluation of Function to Avoid CardioToxicity". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03862131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*